A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.
Saved in:
| Title: | A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. |
|---|---|
| Authors: | Schnittger, S.1 susanne.schnittger@mll-online.com, Bacher, U.2, Kern, W.1, Haferlach, T.1, Hertenstein, B.3, Haferlach, C.1 |
| Source: | Leukemia (08876924). Apr2008, Vol. 22 Issue 4, p856-858. 3p. 1 Diagram, 1 Chart, 1 Graph. |
| Database: | Academic Search Ultimate |
| ISSN: | 08876924 |
|---|---|
| DOI: | 10.1038/sj.leu.2404949 |
